Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (51 quarters reported)
$280M in Q4 2013 → $2.05B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Revolution Medicines Inc | 10.1% | Trimmed 8.6% | 1,105,210 | $207M |
| Travere Therapeutics Inc | 6.0% | Added 47% | 2,179,069 | $124M |
| EL Eli Lilly & Co | 5.8% | Unchanged | 98,700 | $118M |
| Madrigal Pharmaceuticals Inc | 4.6% | Added 2.3% | 174,999 | $94M |
| Mirum Pharmaceuticals Inc | 4.6% | Trimmed 1.6% | 798,145 | $93.4M |
| Rhythm Pharmaceuticals Inc | 3.8% | Added 0.4% | 692,598 | $76.9M |
| Kymera Therapeutics Inc | 2.5% | Trimmed 8.8% | 453,156 | $52M |
| Argenx Se | 2.4% | Trimmed 46% | 52,750 | $48.9M |
| Ascendis Pharma A/s | 2.2% | New | 168,750 | $45M |
| Xenon Pharmaceuticals Inc | 2.0% | Trimmed 10% | 683,907 | $41.3M |
| SR Scholar Rock Hldg Corp | 1.9% | Trimmed 3.3% | 715,452 | $39.3M |
| Insmed Inc | 1.9% | Added 15% | 362,150 | $38.6M |
| Penumbra Inc | 1.8% | Trimmed 3.9% | 115,750 | $36.5M |
| Structure Therapeutics Inc | 1.7% | Added 0.0% | 640,317 | $34.4M |
| UP Ultragenyx Pharmaceutical In | 1.6% | Trimmed 21% | 967,855 | $32.3M |
| Irhythm Holdings Inc | 1.6% | Added 3.0% | 269,650 | $32.1M |
| Intuitive Surgical Inc | 1.5% | Trimmed 6.8% | 76,460 | $30.4M |
| Agilon Health Inc | 1.4% | Added 1.0% | 262,600 | $28.1M |
| Unitedhealth Group Inc | 1.3% | Added 20% | 63,750 | $26.5M |
| CT Celldex Therapeutics Inc New | 1.3% | Added 7.5% | 699,146 | $26M |
| Erasca Inc | 1.3% | Added 27% | 1,402,150 | $25.7M |
| Neurocrine Biosciences Inc | 1.2% | Trimmed 3.8% | 144,750 | $24.4M |
| Enliven Therapeutics Inc | 1.2% | Trimmed 44% | 464,625 | $23.6M |
| Tenet Healthcare Corp | 1.1% | Unchanged | 125,000 | $23.4M |
| Dexcom Inc | 1.1% | Trimmed 3.5% | 343,000 | $23.1M |
| Aclaris Therapeutics Inc | 1.1% | Trimmed 3.2% | 4,330,532 | $22.9M |
| Minimed Group Inc | 1.1% | Added 44% | 1,520,000 | $22.7M |
| Boston Scientific Corp | 1.1% | Added 2.6% | 528,500 | $22.6M |
| Pharvaris N V | 1.1% | Added 0.4% | 648,333 | $22.4M |
| AP Avalyn Pharmaceuticals Inc | 1.1% | New | 662,918 | $21.8M |
| HT Hemab Therapeutics Hldgs Inc | 1.0% | New | 575,432 | $21.1M |
| Dyne Therapeutics Inc | 1.0% | Trimmed 3.1% | 942,154 | $20.9M |
| Alnylam Pharmaceuticals Inc | 1.0% | Trimmed 9.8% | 66,750 | $20.1M |
| Cogent Biosciences Inc | 1.0% | Trimmed 17% | 515,917 | $20M |
| Agios Pharmaceuticals Inc | 1.0% | Trimmed 33% | 532,563 | $19.8M |
| NP Newamsterdam Pharma Company | 1.0% | Trimmed 1.0% | 582,744 | $19.7M |
| Vera Therapeutics Inc | 0.9% | Trimmed 15% | 427,584 | $18.3M |
| Tarsus Pharmaceuticals Inc | 0.9% | Added 23% | 277,087 | $17.4M |
| Heartflow Inc | 0.8% | Added 0.2% | 573,500 | $16.8M |
| Mbx Biosciences Inc | 0.8% | Added 3.6% | 298,218 | $16.5M |
| Cytokinetics Inc | 0.8% | Added 314% | 187,980 | $16M |
| Bicara Therapeutics Inc | 0.8% | Added 9.4% | 535,286 | $15.9M |
| PM Parabilis Medicines Inc | 0.8% | New | 578,028 | $15.8M |
| Zai Lab Ltd | 0.8% | Unchanged | 814,707 | $15.5M |
| DD Danaher Corp Del | 0.7% | Added 24% | 76,300 | $14.5M |
| Tango Therapeutics Inc | 0.7% | Added 18% | 456,551 | $14.3M |
| Evolent Health Inc | 0.7% | Trimmed 6.5% | 2,500,000 | $13.6M |
| Ptc Therapeutics Inc | 0.6% | Added 0.3% | 162,298 | $13.2M |
| Mineralys Therapeutics Inc | 0.6% | Added 10% | 484,951 | $13.1M |
| Zenas Biopharma Inc | 0.6% | Unchanged | 502,077 | $12.7M |
| Ardelyx Inc | 0.6% | Trimmed 2.5% | 2,241,769 | $11.4M |
| IM Inspire Med Sys Inc | 0.5% | Added 85% | 244,000 | $10.9M |
| Bridgebio Pharma Inc | 0.5% | Added 13% | 144,750 | $10.8M |
| Alkermes PLC | 0.5% | Added 8.6% | 199,811 | $10.5M |
| Summit Therapeutics Inc | 0.5% | Added 0.7% | 715,000 | $10.4M |
| Azenta Inc | 0.5% | Trimmed 29% | 403,000 | $10.3M |
| Indivior Pharmaceuticals Inc | 0.5% | Added 23% | 245,500 | $10.1M |
| Stryker Corporation | 0.4% | Added 96% | 29,000 | $9.13M |
| Amylyx Pharmaceuticals Inc | 0.4% | Unchanged | 499,764 | $8.98M |
| Caris Life Sciences Inc | 0.4% | Trimmed 13% | 487,500 | $8.69M |
Showing top 60 of 104 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ascendis Pharma A/s | New | +168,750 | +$45M | 2.2% |
| Ascendis Pharma A/s | Exited | −194,000 | −$44.4M | — |
| Argenx Se | Trimmed | −45,750 | −$42.4M | 2.4% |
| Travere Therapeutics Inc | Added | +701,115 | +$39.8M | 6.0% |
| AP Avalyn Pharmaceuticals Inc | New | +662,918 | +$21.8M | 1.1% |
| HT Hemab Therapeutics Hldgs Inc | New | +575,432 | +$21.1M | 1.0% |
| Revolution Medicines Inc | Trimmed | −104,255 | −$19.5M | 10.1% |
| Arcellx Inc | Exited | −169,859 | −$19.5M | — |
| Enliven Therapeutics Inc | Trimmed | −361,875 | −$18.4M | 1.2% |
| PM Parabilis Medicines Inc | New | +578,028 | +$15.8M | 0.8% |
Showing the 10 largest of 100 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Exact Sciences Corp | Exited | −601,800 | −$61.1M | — |
| Cidara Therapeutics Inc | Exited | −204,878 | −$45.3M | — |
| AT Amicus Therapeutic | Trimmed | −1,908,869 | −$27.6M | — |
| SS SPDR Series Trust | Trimmed | −192,000 | −$24.5M | 0.2% |
| Travere Therapeutics Inc | Trimmed | −732,368 | −$21.8M | 2.6% |
| Madrigal Pharmaceuticals Inc | Added | +31,381 | +$16.4M | 5.3% |
| Minimed Group Inc | New | +1,055,000 | +$15.7M | 0.9% |
| Revolution Medicines Inc | Trimmed | −125,805 | −$12.2M | 6.9% |
| Cogent Biosciences Inc | Trimmed | −224,875 | −$8.66M | 1.4% |
| Boston Scientific Corp | Added | +116,250 | +$7.29M | 1.9% |
Showing the 10 largest of 83 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | Exited | −597,051 | −$56.2M | — |
| Argenx Se | Trimmed | −39,500 | −$33.2M | 4.5% |
| Akero Therapeutics Inc | Exited | −626,526 | −$29.7M | — |
| Structure Therapeutics Inc | Trimmed | −202,918 | −$14.1M | 2.7% |
| Unitedhealth Group Inc | New | +40,800 | +$13.5M | 0.7% |
| Insmed Inc | Trimmed | −65,750 | −$11.4M | 2.8% |
| Cidara Therapeutics Inc | Trimmed | −44,524 | −$9.83M | 2.3% |
| Mereo Biopharma Group PLC | Exited | −4,570,649 | −$9.42M | — |
| SS SPDR Series Trust | Added | +70,250 | +$8.57M | 1.4% |
| Immunome Inc | New | +347,666 | +$7.47M | 0.4% |
Showing the 10 largest of 89 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | Trimmed | −466,557 | −$43.9M | 3.3% |
| Argenx Se | Trimmed | −33,000 | −$24.3M | 6.2% |
| Blueprint Medicines Corp | Exited | −185,500 | −$23.8M | — |
| Insmed Inc | Trimmed | −140,000 | −$20.2M | 3.2% |
| Unitedhealth Group Inc | Exited | −50,500 | −$15.8M | — |
| Oscar Health Inc | Exited | −700,000 | −$15M | — |
| Rhythm Pharmaceuticals Inc | Trimmed | −144,051 | −$14.5M | 4.2% |
| AH Acadia Healthcare Company In | Trimmed | −526,000 | −$13M | 0.2% |
| Alnylam Pharmaceuticals Inc | Trimmed | −25,750 | −$11.7M | 2.0% |
| Cidara Therapeutics Inc | Added | +115,269 | +$11M | 1.4% |
Showing the 10 largest of 79 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Blueprint Medicines Corp | Trimmed | −822,069 | −$105M | 1.5% |
| Nuvalent Inc | Trimmed | −334,204 | −$25.5M | 0.4% |
| Neurocrine Biosciences Inc | Trimmed | −190,200 | −$23.9M | 0.7% |
| Agios Pharmaceuticals Inc | Added | +647,565 | +$21.5M | 2.1% |
| Caris Life Sciences Inc | New | +793,651 | +$21.2M | 1.3% |
| Legend Biotech Corp | Exited | −512,932 | −$17.4M | — |
| Omada Health Inc | New | +919,951 | +$16.8M | 1.0% |
| Unitedhealth Group Inc | Trimmed | −50,000 | −$15.6M | 1.0% |
| Warby Parker Inc | Exited | −835,000 | −$15.2M | — |
| Kymera Therapeutics Inc | Trimmed | −344,063 | −$15M | 1.2% |
Showing the 10 largest of 82 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Intuitive Surgical Inc | Trimmed | −114,000 | −$56.5M | 2.9% |
| Neurocrine Biosciences Inc | Trimmed | −441,500 | −$48.8M | 1.8% |
| Freshpet Inc | Exited | −327,500 | −$48.5M | — |
| Unitedhealth Group Inc | Trimmed | −75,500 | −$39.5M | 3.0% |
| Travere Therapeutics Inc | Trimmed | −2,052,453 | −$36.8M | 3.0% |
| Madrigal Pharmaceuticals Inc | Trimmed | −98,514 | −$32.6M | 3.2% |
| Argenx Se | Trimmed | −53,850 | −$31.9M | 6.0% |
| Alnylam Pharmaceuticals Inc | Trimmed | −112,950 | −$30.5M | 2.2% |
| Insulet Corp | Exited | −114,250 | −$29.8M | — |
| EL Eli Lilly & Co | Trimmed | −31,000 | −$25.6M | 5.4% |
Showing the 10 largest of 95 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Unitedhealth Group Inc | Trimmed | −118,250 | −$59.8M | 3.4% |
| Humana Inc | Exited | −148,000 | −$46.9M | — |
| Exact Sciences Corp | Trimmed | −697,500 | −$39.2M | 1.0% |
| SR Scholar Rock Hldg Corp | New | +716,782 | +$31M | 1.2% |
| Neurocrine Biosciences Inc | Trimmed | −218,500 | −$29.8M | 3.7% |
| Align Technology Inc | Exited | −114,500 | −$29.1M | — |
| Blueprint Medicines Corp | Added | +328,123 | +$28.6M | 3.6% |
| Intuitive Surgical Inc | Trimmed | −54,000 | −$28.2M | 4.3% |
| Freshpet Inc | Trimmed | −119,000 | −$17.6M | 1.8% |
| Tenet Healthcare Corp | New | +129,200 | +$16.3M | 0.6% |
Showing the 10 largest of 90 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Blueprint Medicines Corp | Trimmed | −1,691,641 | −$156M | 2.3% |
| IL Idexx Labs Inc | Exited | −119,500 | −$58.2M | — |
| Evolent Health Inc | Trimmed | −2,007,500 | −$56.8M | 1.9% |
| Boston Scientific Corp | Trimmed | −357,500 | −$30M | 1.3% |
| AH Acadia Healthcare Company In | Trimmed | −362,500 | −$23M | 1.7% |
| Summit Therapeutics Inc | New | +1,040,000 | +$22.8M | 0.7% |
| EL Eli Lilly & Co | Added | +20,500 | +$18.2M | 4.1% |
| Nuvalent Inc | Added | +174,005 | +$17.8M | 1.4% |
| Agios Pharmaceuticals Inc | Trimmed | −344,872 | −$15.3M | 1.0% |
| Zenas Biopharma Inc | New | +878,667 | +$14.9M | 0.5% |
Showing the 10 largest of 79 changes.
Loading...
